Originally posted in Cystic Fibrosis News From Medical News Today

According to Pharmaxis, Bronchitol, a new cystic fibrosis treatment, has been granted EU approval for patients aged 18 years and older as an add-on therapy to the best standard of care in 29 European countries. Dr…

Originally posted in Cystic Fibrosis News From Medical News Today

According to Pharmaxis, Bronchitol, a new cystic fibrosis treatment, has been granted EU approval for patients aged 18 years and older as an add-on therapy to the best standard of care in 29 European countries. Dr…

Originally posted in Cystic Fibrosis News From Medical News Today

Scientists have found why a certain type of bacteria, harmless in healthy people, is so deadly to patients with cystic fibrosis. The bacterium, Burkholderia cenocepacia, causes a severe and persistent lung infection in patients with CF and is resistant to nearly all known antibiotics…

Originally posted in Cystic Fibrosis News From Medical News Today

By developing software that uses 3-D models of proteins involved in cystic fibrosis, a team of scientists at Duke University has identified several new molecules that may ease the symptoms of the disease. Computer algorithms created by the team predict how well a given molecular structure will block a basic protein-protein interaction known to occur in cystic fibrosis…

Originally posted in Cystic Fibrosis News From Medical News Today

Harvard stem cell researchers at Massachusetts General Hospital (MGH) have taken a critical step in making possible the discovery in the relatively near future of a drug to control cystic fibrosis (CF), a fatal lung disease that claims about 500 lives each year, with 1,000 new cases diagnosed annually…

Originally posted in Cystic Fibrosis News From Medical News Today

Researchers at Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) have derived a population of pure lung and thyroid progenitor cells in vitro that successfully mimic the developmental milestones of lung and thyroid tissue formation…

Originally posted in Cystic Fibrosis News From Medical News Today

Cystic fibrosis (CF) is a devastating disease caused by mutations in the CFTR gene. In Canada, one in every 3,600 children born has the disease. Researchers have long been puzzled as to how individuals who carry the same CFTR mutations can experience such different courses of disease. Patients with CF are affected in multiple organs such as the lungs, pancreas and liver, to varying degrees…

Originally posted in Cystic Fibrosis News From Medical News Today

University of North Carolina at Chapel Hill researchers working as part of the International Cystic Fibrosis Consortium have discovered several regions of the genome that may predispose cystic fibrosis (CF) patients to develop an intestinal blockage while still in the uterus. A report of this international study appears online in the journal Nature Genetics…

Originally posted in Cystic Fibrosis News From Medical News Today

When it comes to treating cystic fibrosis, the current standard of aggressive antibiotic treatments may not always be the best answer, a decade-long study led by researchers at the University of Michigan has found…

Originally posted in Cystic Fibrosis News From Medical News Today

A recent study led by Gergely Lukacs, a professor at McGill University’s Faculty of Medicine, Department of Physiology, and published in Cell, has shown that restoring normal function to the mutant gene product responsible for cystic fibrosis (CF) requires correcting two distinct structural defects. This finding could point to more effective therapeutic strategies for CF in the future…

Originally posted in Cystic Fibrosis News From Medical News Today

Kalydeco has been approved by the Food And Drug Administration (FDA) to treat a vicious type of Cystic Fibrosis (CF). CF is a deadly recessive disease which targets the lungs, but can also harm the liver, pancreas, and intestine. It occurs from the unusual transport of chloride and sodium across the epithelium, causing mucus buildup in the lungs, and thick secretions…

Originally posted in Cystic Fibrosis News From Medical News Today

The lung clearance index (LCI) is a sensitive non-invasive marker of early lung disease in young children with cystic fibrosis (CF), according to a new study from Australian researchers…

Originally posted in Cystic Fibrosis News From Medical News Today

According to a new Australian study published online before he print publication in the American Thoracic Society’s American Journal of Respiratory and Critical Care Medicine, the lung clearance index (LCI) is a sensitive, non-invasive marker of early lung disease in young children with cystic fibrosis (CF)…

Originally posted in Cystic Fibrosis News From Medical News Today

Adding inhaled dry powder mannitol to standard therapy for cystic fibrosis produced sustained improvement in lung function for up to 52 weeks, according to a new study. Along with the treatment’s efficacy and good safety profile, the convenience and ease of administration of mannitol treatment may improve adherence with therapy in these patients…

Originally posted in Cystic Fibrosis News From Medical News Today

A new study found that the combination of inhaled dry powder mannitol with standard therapy for cystic fibrosis resulted in maintained improvement in lung function for 12 months. In addition to being effective and safe, the easy administration of the treatment might help enhance adherence with treatment in individuals suffering with the condition…

Originally posted in Cystic Fibrosis News From Medical News Today

Adding inhaled dry powder mannitol to standard therapy for cystic fibrosis produced sustained improvement in lung function for up to 52 weeks, according to a new study. Along with the treatment’s efficacy and good safety profile, the convenience and ease of administration of mannitol treatment may improve adherence with therapy in these patients…

Originally posted in Cystic Fibrosis News From Medical News Today

Results of the pivotal Phase 3 clinical trial published in the Nov. 3, 2011 New England Journal of Medicine, find that the oral medication ivacaftor (VX-770) provides major, sustained improvement in lung function, growth and other signs and symptoms for cystic fibrosis (CF) patients…

Originally posted in Cystic Fibrosis News From Medical News Today

A new study has confirmed that the drug, ivacaftor (VX-770), significantly improves lung function in some people with cystic fibrosis (CF). The results of the phase III clinical trial study, “A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation,” led by Bonnie W…

Originally posted in Cystic Fibrosis News From Medical News Today

A new discovery by Californian scientists may lead to a pharmaceutical breakthrough for a wide range of illnesses that involve the hydration of cells that line the inner surfaces of our body’s organs and tissues…

Originally posted in Cystic Fibrosis News From Medical News Today

New research in The FASEB Journal suggests that cigarette smoke interferes with the Cystic Fibrosis Transmembrane Conductance Regulator protein, leading to dry, sticky mucus and increased infections. If you smoke cigarettes, you have more in common with someone who has cystic fibrosis than you think…

Originally posted in Cystic Fibrosis News From Medical News Today

Cystic fibrosis (CF), a chronic disease that clogs the lungs and leads to life-threatening lung infections, is caused by a genetic defect in a chloride channel called cystic fibrosis transmembrane conductase regulator (CFTR)…

Originally posted in Cystic Fibrosis News From Medical News Today

When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals…

Originally posted in Cystic Fibrosis News From Medical News Today

Researchers have identified an unconventional path that may correct the defect underlying cystic fibrosis, according to a report in the September 2nd issue of the journal Cell, a Cell Press publication. This new treatment dramatically extends the lives of mice carrying the disease-associated mutation…

Originally posted in Cystic Fibrosis News From Medical News Today

A study published on bmj.com indicates, that even though improvements have been made in the last half century for the survival of cystic fibrosis sufferers, females and individuals from socio-economically disadvantaged backgrounds continue to die younger than males and those more privileged in society…

Originally posted in Cystic Fibrosis News From Medical News Today

Azithromycin is an antibiotic that also has antiinflammatory properties. It is these antiinflammatory properties that are thought to account for the improvement in clinical outcome observed when patients with chronic lung diseases such as cystic fibrosis are treated long-term with azithromycin…

Originally posted in Cystic Fibrosis News From Medical News Today

Case Western Reserve University School of Medicine has received a $2.1 million grant from the National Center for Research Resources, part of the National Institutes of Health (NIH), to expand basic research models for the study of cystic fibrosis (CF). CF is an inherited disease that causes thick, sticky mucus to build up in the lungs and digestive tract…

Originally posted in Cystic Fibrosis News From Medical News Today

A comparative study published in July 13 issue of JAMA noticed, treatment based on a new invasive diagnostic procedure for treating cystic fibrosis in infants that involves obtaining and culturing fluid samples from the lungs, when compared with standard diagnostic procedure, did not have a lower prevalence of lung-damaging infection or structural lung injury at 5 years of age…

Originally posted in Cystic Fibrosis News From Medical News Today

Astra Biotech GmbH is in the pre-launch phase of its newly developed test, based on microarray technology, for rapid simultaneous detection of 25 of the most common mutations causing cystic fibrosis in pan-European populations. This initiative supports Astra Biotech’s aim of facilitating early diagnosis of individuals’ risk factors through innovative assays…

Originally posted in Cystic Fibrosis News From Medical News Today

PTC Therapeutics, Inc. (PTC) announced the publication of data from a Phase 2 study of ataluren, an investigational new drug, in adults with nonsense mutation cystic fibrosis (nmCF) in the European Respiratory Journal…

Originally posted in Cystic Fibrosis News From Medical News Today

An international research team led by Queen’s University have developed a ground breaking treatment for Cystic Fibrosis sufferers. The new drug will benefit sufferers who have the ‘Celtic Gene’, a genetic mutation which is particularly common in Ireland…